Report: IBM Watson delivered ‘unsafe and inaccurate’ cancer recommendations

Internal documents from IBM Watson Health (NYSE:IBM) indicate that the company’s Watson for Oncology product often returns “multiple examples of unsafe and incorrect treatment recommendations,” according to a new report from STAT News. The documents come from slides presented last year by IBM Watson Health’s deputy chief health officer, according to the report, and include feedback from customers that indicated the product is “often inaccurate” and that its recommendations bring to light “serious questions about the process for building content and the underlying technology.” The issues were blamed on training the Watson product received by IBM engineers and physicians at the Memorial Sloan Kettering Cancer Center, which included “synthetic,” or hypothetical patients and cases, instead of real patient data, STAT reports. IBM has not publicly acknowledged the issues, according to the report, and has communicated to its customers that all data included in Watson for Oncology is based on real patients and that the product has won praise around the world for its recommendations. Earlier this year, IBM cognitive solutions division senior VP John Kelly touted that Watson “has ingested all of the Memorial Sloan data, historic patients and results,” at an IBM event, and also commented that the company’s Watson product was “going fabulously,” STAT reports. “It’s critical that eve...
Source: Mass Device - Category: Medical Devices Authors: Tags: Oncology Software / IT IBM Watson Health Source Type: news

Related Links:

Cancer is one of the leading causes for the morbidity and mortality worldwide. Although substantial studies have been conducted theoretically and experimentally in recent years, it is still a challenge to expl...
Source: BMC Systems Biology - Category: Molecular Biology Authors: Tags: Software Source Type: research
Lab Chip, 2018, Accepted Manuscript DOI: 10.1039/C8LC01071D, PaperPeng Zhang, Jennifer Crow, Divya Jyothi Lella, Xin Zhou, Glenson Samuel, Andrew K Godwin, Yong Zeng Extracellular vesicles (EVs) present a promising liquid biopsy for cancer diagnosis. However, it remains a daunting challenge to quantitatively measure molecular contents of EVs including tumor-associated mRNAs. Herein, we report... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Lab Chip latest articles - Category: Chemistry Authors: Source Type: research
Dalton Trans., 2018, Accepted Manuscript DOI: 10.1039/C8DT03948H, CommunicationYuanyuan You, Ni Wang, Lizhen He, Changzheng Shi, Dong Zhang, Yiyong Liu, Liangping Luo, Tianfeng Chen Herein we design and synthesize a cell penetration peptide- and cancer-targeted molecule-functionalized multi-walled carbon nanotube for precise orthotopic glioma therapy. This nanosystem demonstrates improved cancer recognition, blood-brain barrier (BBB) penetration,... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
Authors: Alshangiti A, Chandhoke G, Ellis PM Abstract Angiogenesis is frequent in non-small-cell lung cancer (nsclc) and is associated with more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic therapy to standard therapies for patients with nsclc. Bevacizumab, a monoclonal antibody directed against serum vascular endothelial growth factor, in combination with carboplatin-paclitaxel chemotherapy, has been shown to improve survival for patients with nsclc. However, bevacizumab-based therapy is not suitable for many nsclc patients, including those with squamous histology, poor pe...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
AbstractPatients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. We find that for the majority of primary and treated metastatic brain tumors, the risk of spontaneous bleeding is acceptable and not further increased by careful therapeutic anticoagul...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Neuro-Oncology, Symptom Management and Supportive Care Source Type: research
Abstract Upregulation of angiogenesis is a frequent occurrence in lung cancer and is reported to represent a negative prognostic factor. This provides a rationale for the development and evaluation of anti-angiogenic agents. To date bevacizumab, a monoclonal antibody directed against serum VEGF, is the only anti-angiogenic agent that has demonstrated improved overall survival for patients with lung cancer. Meta-analysis of trials of bevacizumab in combination with platinum-based chemotherapy for NSCLC, show a 10 % reduction in the risk of death (HR 0.90, 95 % CI 0.81-0.99). However, therapy with bevacizumab is lim...
Source: Adv Data - Category: Epidemiology Authors: Tags: Adv Exp Med Biol Source Type: research
"The patient's skull was struck by a baseball bat. He has a perfectly legitimate reason for subarachnoid hemorrhage. He already had a CT [computed tomogram] of the head showing the bleed in good detail. Why another?" I remonstrated with Watson, the neurosurgeon. "But you don't know that there is no intracranial aneurysm. You can't rule that out. He needs a CT angiogram of the brain immediately," protested Watson. Hit by a hard object (cause) and blood in brain (effect) is deductive reasoning at its simplest. But Watson was correct: I could not rule out cerebral artery aneurysm without a CT angiogram. I ...
Source: British Journal of Sports Medicine - Category: Sports Medicine Authors: Tags: Republished research from the BMJ Source Type: research
Blood clots can be lifesavers when they form outside the bloodstream to stop bleeding from an injury. But they can wreak havoc when they form inside the bloodstream. A blood clot in a coronary artery can cause a heart attack. One in the brain can cause a stroke. Blood clots that form in a leg vein cause a problem known as venous thromboembolism, or VTE. If the clot stays in the leg, it can cause swelling or pain. If it breaks away and travels to the lungs, it can cause a potentially deadly pulmonary embolism. In about half of people who develop a VTE, doctors can identify what caused it. Common causes include an injury; su...
Source: New Harvard Health Information - Category: Consumer Health News Authors: Tags: Cancer blood clot venous thromboembolism VTE Source Type: news
Conclusions: Bevacizumab-based therapy proved to be feasible and safe. The PFS and the OS data are very encouraging as well as the symptomatic benefit due to bevacizumab's high capacity to provide a long-lasting decrease of perilesional edema.Chemotherapy 2014;60:294-299
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: PH presents in a stereotyped fashion and although it is an exclusion diagnosis it should be considered in a patient with visual hallucinations. Evidence for treatment is limited, however atypical antipsychotics have been reported useful in this condition, as in our case. Study Supported by: Hospital Universitario Fundación Santa Fe de BogotáDisclosure: Dr. Burbano has nothing to disclose. Dr. Toro has received personal compensation in an editorial capacity for New England Journal of Medicine Journal Watch Neurology and Multiple Sclerosis and Related Disorders.
Source: Neurology - Category: Neurology Authors: Tags: Neurotherapeutics Source Type: research
More News: Avastin | Bleeding | Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Hospitals | Lung Cancer | Lung Transplant | Marketing | Neurology | Science | Study | Training | Universities & Medical Training | Warnings